Company recognized for innovations in clinically validated cell therapy for corneal endothelial dystrophies
Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Efficacy data from Escalón study shows improvements in central corneal thickness and best corrected visual acuity May 2, 2023 – Seattle, Cambridge and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2023 American Society of Cataract and Refractive Surgery (ASCRS)…
March Milestone
By Greg Kunst, CEO A lot of things seem to happen in March – Caesar’s assassination, Shakespeare’s Ides (a fortune-teller’s warning of the aforementioned assassination), the Spring Equinox, and (of course) March Madness.But Aurion’s most recent March Milestone augurs only good things – especially for the millions of patients around the world who suffer from…
Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application
First approval in the world forallogeneic cell therapy to treat corneal endothelial disease March 23, 2023 – Seattle, Cambridge MA and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMD A),…
Advanced Therapies for Ocular Diseases
We are a clinical-stage biotech company. We aim to restore vision to all who need it by developing a platform of innovative, accessible, and effective advanced therapies. Our first candidate is a patented cell therapy treatment for corneal endothelial disease.